Akari Therapeutics (AKTX) Non Operating Income (2014 - 2026)
Akari Therapeutics recorded quarterly Non Operating Income of $444000.0 in Q1 2026, up 122.36% quarter-over-quarter from -$2.0 million in Q4 2025, and up 346.67% year-over-year from $99403.0 in Q1 2025.
Akari Therapeutics' Non Operating Income history runs 13 years deep, the most recent figure standing at $444000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 346.67% year-over-year to $444000.0; the TTM figure through Mar 2026 stood at -$402000.0 (up 98.58% YoY), while the FY2025 annual figure was -$1.0 million, down 155.4% from the prior year.
- Non Operating Income came in at $444000.0 for Q1 2026 at Akari Therapeutics, up from -$2.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.2 million in Q2 2025 to a low of -$28.0 million in Q4 2024.
- A 5-year average of -$1.9 million and a median of -$12000.0 in 2023 frame the typical range for Non Operating Income.
- On a YoY basis, Non Operating Income climbed as much as 3945.45% in 2024 and fell as far as 3041.91% in 2024.
- Akari Therapeutics' Non Operating Income stood at $136174.0 in 2022, then jumped by 599.11% to $952000.0 in 2023, then tumbled by 3041.91% to -$28.0 million in 2024, then surged by 92.91% to -$2.0 million in 2025, then soared by 122.36% to $444000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $444000.0, -$2.0 million, and -$84000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -8.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 444,000.00 |
| Dec 31, 2025 | -1.99 Mn |
| Sep 30, 2025 | -84,000.00 |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | -180,000.00 |
| Dec 31, 2024 | -28.01 Mn |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | -109,000.00 |
| Mar 31, 2024 | 423,000.00 |
| Dec 31, 2023 | 6.84 Mn |
| Sep 30, 2023 | -364,000.00 |
| Jun 30, 2023 | -13,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Jun 30, 2022 | 136,174.00 |
| Dec 31, 2021 | 294,107.00 |
| Sep 30, 2021 | 12,041.00 |
| Jun 30, 2021 | -16,334.00 |
| Mar 31, 2021 | -289,831.00 |
| Dec 31, 2020 | 85,659.00 |
| Sep 30, 2020 | 1.16 Mn |
| Jun 30, 2020 | -1.53 Mn |
| Mar 31, 2020 | 1.18 Mn |
| Dec 31, 2019 | -3,710.00 |
| Sep 30, 2019 | 235,426.00 |
| Jun 30, 2019 | 83,674.00 |
| Mar 31, 2019 | -198,473.00 |
| Dec 31, 2018 | 1.22 Mn |
| Sep 30, 2018 | -607,312.00 |
| Jun 30, 2018 | -43,291.00 |
| Mar 31, 2018 | 2.97 Mn |
| Dec 31, 2017 | 1.49 Mn |
| Sep 30, 2017 | -1.84 Mn |
| Jun 30, 2017 | 7.03 Mn |
| Mar 31, 2017 | -4.30 Mn |
| Dec 31, 2016 | 1.57 Mn |
| Sep 30, 2016 | 5.60 Mn |
| Jun 30, 2016 | 1.07 Mn |
| Mar 31, 2016 | 866,594.00 |
| Dec 31, 2015 | 10.76 Mn |
| Sep 30, 2015 | -25.41 Mn |
| Jun 30, 2015 | -28,755.00 |
| Mar 31, 2015 | -42,157.00 |
| Dec 31, 2014 | -8,672.00 |
| Sep 30, 2014 | -5,100.00 |
| Jun 30, 2014 | 101,000.00 |
| Mar 31, 2014 | 143,000.00 |